Item 2.02. Results of Operations and Financial Condition.

On January 13, 2022, Accelerate Diagnostics, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the quarter ending December 31, 2021 and full-year 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

Item 7.01. Regulation FD Disclosure.

On January 13, 2022, the Company will make a presentation at the 2022 J.P. Morgan Healthcare Conference. A copy of the presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference in its entirety. The presentation also will be posted to the investor relations section of the Company's website at: http://ir.axdx.com/.

In accordance with General Instruction B.2 for Form 8-K, the information in Items 2.02 and 7.01 of this Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.






 (d) Exhibits.




Exhibit
Number     Description

  99.1       Press Release, dated January 13, 2022

  99.2       Accelerate Diagnostics Presentation for 2022 J.P. Morgan Healthcare
           Conference

104        Cover Page Interactive Data File (cover page XBRL tags are embedded
           within the Inline XBRL document)

© Edgar Online, source Glimpses